{"doi":"10.1101/2020.04.15.20065623","title":"Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients","abstract":"<jats:title>Abstract</jats:title>\n                <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>COVID-19 is a pandemic with no specific antiviral treatments or vaccines. The urgent needs for exploring the neutralizing antibodies from patients with different clinical characteristics are emerging.</jats:p>\n                </jats:sec>\n                <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>A total of 117 blood samples were collected from 70 COVID-19 inpatients and convalescent patients. The presence of neutralizing antibody was determined with a modified cytopathogenic assay based on live SARS-CoV-2. The dynamics of neutralizing antibody levels at different with different clinical characteristics were analyzed.</jats:p>\n                </jats:sec>\n                <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>\n                    The seropositivity rate reached up to 100.0% within 20 days since onset, and remained 100.0% till day 41-53. The total GMT was 1:163.7 (95% CI, 128.5 to 208.6), and the antibody level was highest during day 31-40 since onset, and then decreased slightly. Individual differences in changes of antibody levels were observed among 8 representative convalescent patients. In multivariate GEE analysis, patients at age of 31-60 and 61-84 had a higher antibody level than those at age of 16-30 (β=1.0518,\n                    <jats:italic>P</jats:italic>\n                    =0.0152; β=1.3718,\n                    <jats:italic>P</jats:italic>\n                    =0.0020). Patients with a worse clinical classification had a higher antibody titer (β=0.4639,\n                    <jats:italic>P</jats:italic>\n                    =0.0227).\n                  </jats:p>\n                </jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions</jats:title>\n                  <jats:p>The neutralizing antibodies were detected even at the early stage of disease, and a significant response showed in convalescent patients. Moreover, changes on antibody levels ware individual specific.</jats:p>\n                </jats:sec>","journal":null,"year":null,"id":603457,"datarank":0.7712495334753992,"base_score":5.14166355650266,"endowment":5.14166355650266,"self_citation_contribution":0.7712495334753992,"citation_network_contribution":0.0,"self_endowment_contribution":0.7712495334753992,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":170,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1548015,"name":"Xianghua Guo","orcid":null,"position":1,"is_corresponding":false},{"id":985534,"name":"Qianqian Xin","orcid":"0000-0002-4342-7974","position":2,"is_corresponding":false},{"id":1548016,"name":"Yanhui Chu","orcid":null,"position":3,"is_corresponding":false},{"id":1346179,"name":"Jing Li","orcid":"0000-0003-3209-8973","position":4,"is_corresponding":false},{"id":57050,"name":"Yang Pan","orcid":null,"position":5,"is_corresponding":false},{"id":1548017,"name":"Yingmei Feng","orcid":null,"position":6,"is_corresponding":false},{"id":106031,"name":"Quanyi Wang","orcid":"0000-0001-9552-2503","position":7,"is_corresponding":false},{"id":112529,"name":"Xiaoli Wang","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients","abstract":"<jats:title>Abstract</jats:title>\n                <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>COVID-19 is a pandemic with no specific antiviral treatments or vaccines. The urgent needs for exploring the neutralizing antibodies from patients with different clinical characteristics are emerging.</jats:p>\n                </jats:sec>\n                <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>A total of 117 blood samples were collected from 70 COVID-19 inpatients and convalescent patients. The presence of neutralizing antibody was determined with a modified cytopathogenic assay based on live SARS-CoV-2. The dynamics of neutralizing antibody levels at different with different clinical characteristics were analyzed.</jats:p>\n                </jats:sec>\n                <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>\n                    The seropositivity rate reached up to 100.0% within 20 days since onset, and remained 100.0% till day 41-53. The total GMT was 1:163.7 (95% CI, 128.5 to 208.6), and the antibody level was highest during day 31-40 since onset, and then decreased slightly. Individual differences in changes of antibody levels were observed among 8 representative convalescent patients. In multivariate GEE analysis, patients at age of 31-60 and 61-84 had a higher antibody level than those at age of 16-30 (β=1.0518,\n                    <jats:italic>P</jats:italic>\n                    =0.0152; β=1.3718,\n                    <jats:italic>P</jats:italic>\n                    =0.0020). Patients with a worse clinical classification had a higher antibody titer (β=0.4639,\n                    <jats:italic>P</jats:italic>\n                    =0.0227).\n                  </jats:p>\n                </jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions</jats:title>\n                  <jats:p>The neutralizing antibodies were detected even at the early stage of disease, and a significant response showed in convalescent patients. Moreover, changes on antibody levels ware individual specific.</jats:p>\n                </jats:sec>","is_dataset_classified":null,"base_score":5.14166355650266,"endowment":5.14166355650266,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23304386","pmcid":null,"openalex_id":"https://openalex.org/W3032963939","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[{"year":2020,"count":85},{"year":2021,"count":70},{"year":2022,"count":9},{"year":2023,"count":4},{"year":2024,"count":2}],"oa_status":"green","license":null,"oa_locations":[{"url":"https://www.medrxiv.org/content/medrxiv/early/2020/04/23/2020.04.15.20065623.full.pdf","host_type":"repository"},{"url":"https://www.medrxiv.org/content/medrxiv/early/2020/04/23/2020.04.15.20065623.full.pdf","host_type":"repository"},{"url":"https://syndication.highwire.org/content/doi/10.1101/2020.04.15.20065623","host_type":"publisher"},{"url":"https://doi.org/10.1101/2020.04.15.20065623","host_type":"repository"}],"fields_of_study":["SARS-CoV-2 and COVID-19 Research","COVID-19 Clinical Research Studies","Long-Term Effects of COVID-19"],"mesh_terms":[],"keywords":["Antibody","Convalescent plasma","Neutralizing antibody","Medicine","Titer","Coronavirus disease 2019 (COVID-19)","Immunology","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","Antibody response","Virology","Antibody titer","Convalescence","Internal medicine","Disease","Infectious disease (medical specialty)"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T22:01:11.017428Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}